Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Birth represents a functional watershed in the developing immune system. In utero, the fetus is exposed to a constant barrage of “foreign” antigens that are derived mainly from the mother and must downregulate its immune responses to survive. However, after birth, the neonatal immune system is exposed to a new, more varied set of antigens and must evolve dichotomous responses to simultaneously “contain” microbial populations on various cutaneous and mucosal surfaces and also develop tolerance to commensal microbes and dietary macromolecules. While some components of the neonatal immune system perform adequately and on par with adults, immaturity of several major arms of immunity results in a developmentally regulated, transient state of immunodeficiency during early infancy. This chapter highlights major strengths and limitations of the neonatal immune system.
The immunologic system is broadly comprised of two major host defense mechanisms: innate, or nonspecific, immune mechanisms, and the acquired, or specific, immune mechanisms. By definition, innate immunity includes host defense mechanisms that operate effectively without prior exposure to a microorganism or its antigens. Some of these mechanisms include physical barriers, such as intact skin and mucous membranes, and chemical barriers, such as gastric acid and digestive enzymes. Beneath these important protective layers lie phagocytic cells, which constitute the first line of host defense against any microbes that breach the cutaneous and mucosal barriers. Soluble plasma and tissue proteins serve to amplify the function of the phagocytic cells as innate immune effectors. Acquired, or specific, immunity comprises primarily the cell-mediated (T lymphocyte) and the humoral (B lymphocyte and immunoglobulin) systems.
Both innate and acquired immune mechanisms are necessary for an individual to be fully immunocompetent. These systems are intimately interrelated and interdependent. Phagocytes such as neutrophils and the cells of the monocytes–macrophage lineage are important effectors of innate immunity, because these cells function to ingest and clear microbial pathogens from normal tissues. Monocytes and macrophages also process microbial antigenic material for presentation to T lymphocytes, a pivotal step in the initiation of the adaptive immune response.
During fetal development, hematopoiesis first begins in the extra-embryonic mesoderm of the yolk sac and later shifts to the liver and then to the marrow. Yolk sac hematopoiesis continues from the 3rd through the 8th-10th week. Hepatic hematopoiesis begins in the 5th week and continues through 20-24 weeks and is mainly erythropoietic; although myeloid progenitors are abundant in the liver, mature neutrophils are not identifiable. Hematopoiesis is observed in the marrow by the 11th week, when committed granulocytic progenitors are first seen in the clavicular marrow. As gestation proceeds to the 20th week, the bone marrow becomes the major site of hematopoiesis and thereafter remains the primary reservoir for replenishing circulating populations of immune cells.
All the cellular components of the immunologic system have limited life spans, and the cells must be constantly replenished from a pool of undifferentiated precursor cells derived from a pluripotent stem cell. Through mechanisms that are not well understood, pluripotent stem cells are stimulated to divide and differentiate into committed progenitor cells that mature into circulating blood cells. Progenitor expansion and differentiation is normally driven and regulated by a variety of growth factors supplied by fibroblasts, endothelial cells, and macrophages present in the microenvironment of the hematopoietic stem cells. Emerging evidence also indicates a role for the local extracellular matrix; specific matrix-associated glycoproteins may favor one cellular lineage over another.
Pluznick and Sachs and Bradley and Metcalf first cultured hematopoietic progenitor cells in semisolid media and named these progenitors colony-forming units (CFUs). CFUs producing a mixture of granulocytes, macrophages, and erythrocytes were called CFU-MIX , whereas the CFUs producing granulocytes, macrophages, erythrocytes, and megakaryocytes were called CFU-GEMM . Other CFUs gave rise to only 1-2 cell lineages: CFU-G produced only neutrophils, CFU-M produced monocytes, CFU-GM gave rise to both neutrophils and monocytes, and CFU-Meg produced only megakaryocytes. More recently, development of monoclonal antibodies that recognize cell surface molecules expressed on hematopoietic stem cells has permitted the isolation and characterization of these cells.
The most primitive host defense mechanism involves the ingestion and killing of bacteria and other microorganisms by phagocytic cells. Polymorphonuclear neutrophils (PMNs), monocytes, and macrophages are the major cell types that accomplish this aspect of host defense. Natural killer (NK) cells are also important components of the innate immune system, but these cells kill invading pathogens by non-phagocytic mechanisms. All these cell types can eliminate pathogens from the host, but do so more efficiently when the pathogens are opsonized, or coated, by complement components and other soluble proteins of the innate immune system. Similarly, non-phagocytic methods such as lysis of infected cells by PMNs and macrophages are also augmented in the presence of specific antibody to the target organism. This section provides an overview of neutrophils and monocyte/macrophages, important phagocytic cells mediating the innate immune response.
In the human fetus, granulocytopoiesis takes place almost exclusively in the bone marrow. The PMN system arises from two major hematopoietic progenitors, the CFU-mix and the CFU-GEMM. In the bone marrow, the neutrophil cell lineage includes early precursors, which have a capacity for 4-5 cell divisions (the neutrophil proliferating pool or the NPP), and the later, postmitotic stages that are in the process of differentiation (neutrophil storage pool or NSP). In adults, the NPP contains about 2 × 10 9 cells/kg body weight, and the NSP contains about 6 × 10 9 cells/kg body weight. The NPP and NSP together contain nearly 90% of all neutrophils in the body. The NSP constitutes a reserve pool of mature cells, including metamyelocytes, band neutrophils, and segmented neutrophils that may be rapidly mobilized into the circulation in response to inflammation.
Positive and negative regulators of PMN production have been identified. Positive regulatory factors are interleukin (IL)-3, granulocyte-colony stimulating factor (G-CSF), and the granulocyte-macrophage colony-stimulating factor (GM-CSF). Several negative regulators of PMN production have also been identified, including the interferons (IFNs), transforming growth factor-α, macrophage inflammatory protein-1α (CC motif-ligand 3), prostaglandins, and lactoferrin and other iron-binding proteins. Although the mechanisms by which PMNs are released from the marrow under physiologic conditions are unclear, increasing evidence indicates an important role for the chemokine receptor CXCR4. During inflammation, IL-1, tumor necrosis factor (TNF), epinephrine, and complement fragments can stimulate PMN release from the bone marrow. Once released from the marrow, mature PMNs circulate for approximately 6-8 hours before migrating into tissues, where these cells survive for about an additional 24 hours. While in the bloodstream, half of the PMNs are attached to the microvascular endothelium, mainly in the lungs, and the other half are free in circulation. After PMNs emigrate from the blood vessels and enter a tissue, they do not reenter blood vessels but age and die in the tissue. Although the actual site of PMN clearance is unknown, macrophages may play an important role in ingestion and degradation of senescent apoptotic PMNs.
Mature PMNs are first identified in the fetal bone marrow at approximately 14 weeks of gestation. By 22-23 weeks of gestation, the circulating PMN count increases but remains lower than in term newborns. The fetal blood contains 10- to 50-fold higher concentration of CFU-GM than adult blood, yet the fetus has a much smaller total pool of neutrophil progenitors. One explanation for the high concentration of circulating progenitors is that these stem cells may have left one hematopoietic environment (the liver) for another (the bone marrow).
In the mid-gestation fetus and preterm infant, the NSP is very small in size and can be readily exhausted during sepsis. The NPP is also smaller, about one-tenth the size (per kg body weight) of adults. Interventions such as administration of recombinant granulocyte-colony stimulating factor (G-CSF), granulocyte macrophage-colony stimulating factor (GM-CSF), and corticosteroids can release neutrophils from the NSP. Epinephrine can also rapidly release marginated neutrophils into circulation, and a mild demarginating response may also be observed in preterm infants after red cell transfusions.
Circulating concentrations of PMNs increase dramatically at birth, peak at 12-24 hours, and then decline slowly by 72 hours to remain stable during the rest of the neonatal period. Blood PMN concentrations can be interpreted using one of several available reference ranges. The absolute neutrophil count can be calculated from a routine complete blood count (CBC) by multiplying the white cell count with the sum of segmented and band neutrophil percentages on the differential count. Manroe et al. were the first to compile reference ranges for blood neutrophil concentrations in neonates using data from a cohort of 434 neonates born at 38.9 ± 2.4 weeks’ gestation. They showed that the neutrophil counts peaked at 12-24 hours with 95% confidence limits of 7,800-14,500/µL and then stabilized at a lower value of 1,750 by 72 hours of life. A stable upper limit was achieved at 6.6 days of age. Although these ranges were useful for term and late preterm neonates, these did not include many preterm infants. To address this deficiency, Mouzinho et al. compiled ANC values from 1,788 CBCs drawn from 63 neonates born at 29.9 ± 2.3 weeks’ gestation. Their revised charts were comparable to those from Manroe et al. near the upper limits of blood neutrophil concentrations but showed greater variation at the lower limit. In a more recent study, Schmutz et al. compiled a new set of reference ranges for ANCs using data from 30,354 CBCs from neonates born at 23-42 weeks’ gestation. Besides the large sample size, a major strength of this study was the use of automated blood counting instrumentation, which allowed greater consistency in identification of neutrophils. In the interval between 72 and 240 hours after birth, the ANC ranged between 2700-13,000/µL (5 th -95th percentile) for infants >36 weeks’ gestation, between 1000-12,500/µL at 28-36 weeks, and 1300-15,300/µL at <28 weeks’ gestation. The upper limits of ANC in this data set were higher than ranges reported by both Manroe and Mouzinho, which may have been due to the high altitude at which the participating centers were located.
When searching for the cause of neutropenia (<1500 PMNs/mm 9 ) in infants, a strong suspicion of infection is warranted, although maternal preeclampsia, premature birth, birth depression, intraventricular hemorrhage, and hemolytic disease may result in low peripheral PMN counts. Persistent neutropenia is one feature that is frequently seen in patients who succumb to overwhelming sepsis. Neutropenia in these infants may be due to increased margination of activated circulating cells or to rapid depletion of circulating and bone marrow storage pool PMNs. Failure to provide adequate numbers of PMNs to the sites of microbial invasion may contribute to the risk of overwhelming sepsis in neonates.
The PMN is qualitatively and quantitatively the most effective killing phagocyte of host defense. Numerous coordinated steps are required to attract a large number of PMNs from the circulating blood into a tissue at the site of microbial invasion ( Fig. 47.1 ). During acute inflammation, first mature neutrophils, and then progressively immature cells, are released from the bone marrow storage pool into the circulation. The circulating PMNs exit the intravascular compartment to enter tissue sites of inflammation in three steps: margination and rolling on vascular endothelium, attachment to the endothelial cells, and transendothelial migration. In the face of microbial translocation across cutaneous or mucosal barriers, a variety of chemoattractants recruit circulating PMNs, including microbial products such as N -formyl-methionyl-leucyl-phenylalanine (f-MLP), and host factors such as CXC chemokines (particularly those expressing the tripeptide sequence glutamic acid-leucine-arginine, such as IL-8), products of the complement system (C5a), lipids such as leukotrienes (LTB4) and hepoxilin-A3, collagen fragments containing the tripeptide sequence proline-glycine-proline, and nuclear matrix proteins (such as high-mobility group box-1) that are released during cell death.
PMN adhesion to endothelial cells is a crucial step in the recruitment of these leukocytes to inflammatory sites. Although PMNs can adhere to normal or activated vascular endothelium, inflammation is associated with hemodynamic and biochemical changes in blood vessels that facilitate leukocyte adhesion to the vessel endothelial lining. PMNs flowing through an inflamed venule may transiently adhere to the endothelium to “brake” their flow, causing the neutrophils to “tumble” or “roll” on the vascular surface. Leukocyte rolling is mediated via the interaction of L-selectin molecules on neutrophils with endothelial glycoproteins called addressins ( Fig. 47.2 ): glycosylation-dependent cell adhesion molecule-1 (GlyCAM-1), CD34/sgp90, endomucin, podocalyxin, endoglycan, and the mucosal vascular addressin cell adhesion molecule-1 (MAdCAM-1). Endothelial cells also express two selectin molecules, P-selectin/CD62P and E-selectin/CD62E, which interact with the P-selectin glycoprotein ligand-1 (PSGL-1) and L-selectin on leukocytes. Engagement of these selectins activates signaling pathways in neutrophils that initiate neutrophil rolling and activation.
Circulating neutrophils usually roll along vascular endothelial cells with transient interactions between neutrophil selectins on the cell surface and counter-receptors on the endothelium. When endothelial cells are activated during inflammation, more selectin counter-receptors are expressed, and additional proteins (intercellular adhesion molecule [ICAM]-1 and ICAM-2) of the immunoglobulin supergene family, which serve as ligands for the neutrophil integrin family, are activated. Specific receptor-ligand interactions at the cell surface membrane facilitating neutrophil adhesion to vascular endothelium are shown in Fig. 47.2 .
After a few rolling events, leukocytes slow down and rest on the endothelium. During this phase, the interaction of leukocyte integrins with endothelial receptors initiates signaling events in the endothelium leading to transendothelial migration of leukocytes. Integrins involved in neutrophil trafficking include three heterodimeric proteins, each of which consists of one immunologically distinct “α” subunit (leukocyte functional antigen-1; CD11a, Mac-1; CD11b, p150, 95; CD11c), along with a common “β” subunit (CD18). Monoclonal antibodies directed against CD11b/CD18 inhibit PMN aggregation, spread, chemotaxis, and adhesion to endothelial cells. CD11b/CD18 and CD11c/CD18 serve as complement receptors and mediate complement-coated (fragment iC3b) particle ingestion by PMNs. CD11a/CD18 has been shown to be important in PMN killing of target cells through antibody-dependent mechanisms. Patients with a heritable deficiency of these leukocyte cell surface glycoproteins have recurrent infections characterized by failure to accumulate granulocytes at sites of infection.
Increased interactions of neutrophil cell surface integrins with endothelial ICAM-1 and ICAM-2 results in firm neutrophil-endothelial adhesive interactions. After tight adhesion, the PMN begins a process of diapedesis through adjacent endothelial cells and the intact underlying basement membrane. Once the PMN has penetrated the basement membrane, the cell migrates from the blood vessel into the area of inflammation. In the tissues, initial random migration (chemokinesis) becomes progressively directed (chemotaxis) toward the nidus of microorganisms along concentration gradients of bacterial products or chemotactic factors.
Adhesion of PMNs to artificial surfaces in vitro is comparable for unstimulated PMNs isolated from neonatal or adult blood. When PMNs from term neonates are stimulated with chemotactic factors, adhesion is greatly diminished, however, compared with cells isolated from adults. More profound deficits are displayed by PMNs from preterm infants. Neonatal PMNs show lower selectin expression, defective shedding of L-selectin, and less stimulated mobilization and overall expression of CD11b/CD18 glycoproteins on the plasma membrane. Other causes of diminished stimulated adherence include impaired capacity to upregulate cell surface chemotactic receptors, lower granular content of lactoferrin, less fibronectin binding to the cell surface, and less shape change (failure to increase significantly overall cell surface area on chemotactic factor stimulation). Downregulation of L-selectin expression on term newborn cord blood granulocytes and monocytes during acute inflammation has been shown, although the pattern and level of shedding vary from neutrophils isolated from adult subjects.
Compared to neutrophils from adults, neutrophils from both term and preterm neonates adhere poorly to endothelium. Neonatal neutrophils have lower selectin and β-integrin expression. In neonates, L-selectin expression is lower at birth than in adults and decreases further during the first 24-72 hours. Neonatal “stress,” as in perinatal asphyxia, may further reduce L-selectin expression on neutrophils. In addition, neonatal neutrophils display defective shedding of L-selectin. The combination of lower expression and impaired shedding of L-selectin reduces the frequency of neutrophil rolling events, which are a rate-limiting step in the tissue recruitment of neutrophils. Characteristics of preterm vascular endothelium such as lower P -selectin expression further contribute to these defects in neutrophil recruitment.
Neonatal neutrophils have lower expression of Mac-1(CD11b/CD18), which correlates with lower neutrophil–endothelial adherence and transmigration. In addition, neutrophils from both preterm and term infants are unable to upregulate Mac-1 expression following stimulation by bacterial products.
Transendothelial migration of neutrophils is affected to some degree by deformability of neutrophils. Although initial studies reported conflicting data, deformability of mature resting neutrophils appears to be similar in healthy preterm neonates to their full-term counterparts and adults. However, the release of immature neutrophils from the NSP during sepsis is associated with an overall reduction in neutrophil deformability.
Interventions such as administration of recombinant G-CSF increase the expression of β 2 -integrins but lower L-selectin expression on neonatal neutrophils (both term and preterm). In contrast, early dexamethasone administration decreases β 2 integrin expression on neutrophils.
Chemotaxis is defined as the directed cellular migration along the concentration gradient of a chemoattracting substance. This movement involves a series of orchestrated events, including the binding of the chemoattractant to cell surface receptors, generation of an intracellular second messenger that is coupled to the receptor-ligand binding, and remodeling of the plasma membrane and cytoskeleton to produce shape changes and proper orientation of the cellular contents toward the highest concentration of the chemoattractant. Morphologically, the PMN orients toward the chemoattractant with the formation of a lamellipodium along the leading edge. Most of the intracellular organelles remain at the posterior pole of the cell (uropod). As the cell moves, the leading edge adheres to available surfaces, and contraction of cytoskeletal microfilaments (actin and myosin) pulls along the rest of the cell. Many aspects of this process are poorly developed in PMNs isolated from neonatal blood. Some of the chemotactic defects of PMNs present during the neonatal period persist throughout early childhood.
Neutrophils from both term and preterm neonates have an impaired chemotactic response and migrate slowly compared to adult cells. Although neutrophils from term infants achieve normal chemotactic function by 2 weeks after birth, such postnatal neutrophil maturation begins 2-3 weeks after birth in immature preterm infants and proceeds very slowly. Neutrophils from preterm infants born at 34-36 weeks’ gestation achieve normal chemotaxis by 40-42 weeks’ postconceptional age (PCA). In more immature preterm infants (<34 weeks), neutrophil chemotaxis improves with time but remains impaired in comparison to adults, even at 42 weeks’ PCA. The presence of various clinical confounders makes it difficult to separate the effects of clinical stress from the effects of prematurity on neutrophil function. Gram-negative sepsis may depress neutrophil chemotaxis whereas superficial infections are associated with enhanced chemotaxis.
Neonatal neutrophils bind various chemoattractants normally. However, chemoattractant-induced membrane depolarization, calcium transport, and sugar uptake are relatively less efficient. Neonatal neutrophils show an incremental chemotactic response to increasing chemokine concentrations, but these responses remain lower than adult neutrophils. The chemotactic defect in neonatal neutrophils may be multifactorial, affected by factors such as a larger, poorly motile neutrophil subpopulation; impaired calcium mobilization; and aberrations in intracellular signaling pathways such as NF-B activation. Lower Mac-1 expression can also impede chemotaxis due to impaired neutrophil interaction with the extracellular matrix.
In preterm infants, intrapartum exposure to magnesium sulfate reduces both neutrophil chemotaxis and random motility. Theophylline concentrations in the high therapeutic range (84 µmol/L or 15 µg/mL) cause dose-dependent reductions in neutrophil chemotaxis. Cells from preterm infants are particularly sensitive to this effect. In contrast, theophylline concentrations in the low therapeutic range (28 µmol/L or 5 µg/mL) increase neutrophil activity. Indomethacin, too, has an adverse effect on neutrophil chemotaxis, which is more pronounced in preterm infants. Both G-CSF and GM-CSF increase neutrophil chemotactic responsiveness to other chemoattractants.
Phagocytosis is a process of particle ingestion. Most particulate matter must be opsonized (coated) with IgG, complement fragments C3b or iC3b, fibronectin, or other proteins before being recognized and engulfed by PMNs ( Fig. 47.3 ). Neutrophils express IgG receptors such as Fcγ receptors I-III (or CD16, CD32, CD64), C3b (CR1), and iC3b (CR3). After binding of the opsonized microbe by an appropriate cell surface receptor, the PMN extends pseudopods to surround the particle and form a phagocytic vacuole. Microbes may also be ingested without opsonization through several interactions like lectin-carbohydrates on bacterial fimbriae that interact with neutrophil glycoproteins, protein–protein (such as filamentous hemagglutinin that express the argly-asp), and hydrophobic-protein (bacterial glycolipids and neutrophil integrins) interactions.
Neutrophils from preterm neonates show impaired phagocytosis, which corrects by late third trimester or term gestation to become comparable to adults. Preterm neutrophils ingest particles more slowly and ingest fewer bacteria. The lack of opsonic activity is an important consideration, as preterm infants often have lower concentrations of specific antibodies. Adult neutrophils lose their phagocytic efficiency if suspended in serum of preterm infants. Similarly, neutrophils of preterm neonates can increase their phagocytic function following exposure to adult serum or therapeutic immunoglobulin preparations.
Compared to term neonates and adults, preterm neutrophils have a lower expression of CD16 (F c γRIII) and CD32 (F c γRII), the two most abundant neutrophil IgG receptors. In “stressed” preterm neonates with severe RDS or sepsis, CD16 expression may be even lower. Whereas CD16 expression normally increases to adult levels over the first 3 weeks of life, CD32 deficiency does not correct with time. CD32 is the high-affinity receptor for IgG 2 (important against encapsulated bacteria), and hence CD32 deficiency may represent an important immune defect in preterm neonates. Unlike CD16 and CD32, CD64 expression on neonatal neutrophils (both preterm and term) may be higher than neutrophils from adult subjects. CD64 is not affected by neonatal “stress” as in respiratory distress and/or prolonged rupture of membranes, and emerging data suggest that CD64 might be a useful early marker for bacterial infections.
Recombinant G-CSF and GM-CSF both activate neutrophil phagocytosis. The benefits of intravenous immunoglobulin (IVIG) as a source of opsonic activity remain uncertain. A major limitation may be in the formulation of current IVIG preparations, which may not have adequate concentrations of antibodies against neonatal pathogens.
The phagolysosome provides an enclosed space in which an ingested microbe is exposed to high concentrations of toxic substances while limiting the exposure of the phagocyte and other cells to these potentially injurious agents. The major killing mechanism in neutrophils involves the generation of highly reactive free oxygen radicals in a “respiratory burst.” An NADPH-dependent respiratory burst oxidase localized on the cell membrane (and therefore, the phagosome membrane) reduces molecular oxygen (O 2 ) to superoxide anion (O• 2 - ). Subsequent generation of hydrogen peroxide (H 2 O 2 ) and the hydroxyl radical (OH•, formed in the presence of iron) also contributes to the microbicidal capacity of neutrophils.
These oxygen-dependent bactericidal mechanisms can be broadly divided into myeloperoxidase (MPO)-independent (such as hydrogen peroxide) and MPO-dependent (MPO catalyzes reactions between H 2 O 2 and halides to form highly reactive products). H 2 O 2 is a weak bactericidal agent per se, but the MPO-H 2 O 2 -halide system increases its efficacy by nearly 50-fold. The bactericidal effects of free oxygen radicals are due to oxidizing effects on various components of the bacterial cell wall.
Although preterm neutrophils have a higher oxygen consumption and normal/elevated release of superoxide and H 2 O 2 , the respiratory burst is, overall, depressed. This deficiency may be more marked in preterm infants with a high severity of sickness. Neutrophil oxidative burst remains impaired in preterm infants despite opsonization with IgG and complement.
Perinatal events can influence the respiratory burst in neonatal neutrophils. Labor and vaginal delivery activates the generation of free oxygen radicals in neonatal neutrophils. In contrast, perinatal distress can suppress the neutrophil respiratory burst. Both LPS and cytokines such as interferons and TNF can prime neutrophils for an accelerated respiratory burst in vitro, but prolonged exposure to these agents (during sepsis) can dampen their effect. Reduced respiratory burst activity in preterm infants correlates with impaired intracellular killing of S. aureus or E. coli. Whereas bacterial killing by neutrophils from term neonates has consistently been found to be normal, killing of staphylococci was impaired in preterm neonates.
The postnatal maturation of respiratory burst response varies according to gestational age. During the first week, infants born at 24–28 weeks have a lower respiratory burst than those born at 29-35 weeks. The differences between preterm infants born at different gestational ages disappear in about 2 months, but overall, neutrophils from preterm infants continue to have a weaker oxidative burst than adults. The postnatal maturation of the respiratory burst may not be seen at all in sick preterm infants receiving intensive care.
In “stressed” preterm infants receiving intensive care, recombinant GM-CSF can boost the neutrophil respiratory burst to levels seen in term neonates. Similarly, G-CSF can enhance neutrophil respiratory burst response in septic preterm infants. In adults, hypertonic saline may enhance host response to bacterial challenge by augmenting superoxide formation in neutrophils. Intracellular killing may also be augmented by fluoroquinolones such as ciprofloxacin, which have a potent intraphagosomal bactericidal activity against both gram-positive and gram-negative bacteria.
Neutrophils also contain additional elaborate nonoxidative killing mechanisms, including cationic proteins like defensins, bactericidal/permeability-increasing protein (BPI), and LL-37; proteolytic enzymes such as lysozyme, proteinase 3, and neutrophil elastase; and metal chelator proteins such as lactoferrin. Defensins are broad-spectrum antimicrobial peptides with activity against gram-positive and gram-negative bacteria, fungi, and enveloped viruses. BPI binds lipopolysaccharide (LPS) and blocks its effects, can damage the outer membrane of gram-negative bacteria, and has some opsonic activity. Lactoferrin, an iron chelator, is bacteriostatic as it deprives bacteria of the iron required for growth. Lactoferrin is also involved in neutrophil degranulation, in oxygen radical production, and in granulocytopoiesis. Lysozyme hydrolyzes a glycoside bond in the bacterial cell wall peptidoglycan. Primary granules also contain other cationic antibacterial proteins such as azuricidin, indolicin, and cathelicidins.
Another elegant antimicrobial defense system demonstrated by neutrophils is their ability to form neutrophil extracellular traps (NETs). Upon activation, neutrophils can undergo a type of cell death in which chromatin is released from the cell in the form of NETs. These NETs also contain histones and other antimicrobial proteins that function to trap and kill microbes in the extracellular space. However, neonatal neutrophils are deficient in their ability to form NETs. The mechanisms leading to NET formation and its ability to fight infectious agents is still not well understood and is an active area of investigation.
Neutrophils contain three major types of granules: (1) the “azurophilic” granules (stain positive with the azure A dye), (2) “specific” granules (do not stain with azure A), and (3) “gelatinase” granules. Azurophilic granules contain myeloperoxidase (MPO); proteolytic enzymes such as cathepsin G, proteinase-3, and neutrophil elastase; and antimicrobial proteins such as defensins and the bactericidal permeability-increasing protein (BPI). These granules release their contents into the phagolysosomes and are involved in intracellular killing. The specific granules contain antibacterial agents such as lactoferrin and lysozyme, receptors for complement components, and bacterial products such as f-MLP. Specific granules fuse with the cell membrane to release their contents by exocytosis and also bring functionally important membrane proteins such as integrins, cytochrome- b 558 , and receptors for chemotactic agents and opsonins to the cell surface. Specific granules play an important role in extracellular killing. Gelatinase granules contain fewer antimicrobial cargo but are storage sites for gelatinases and other metalloproteases.
Neutrophils from term neonates have granule content and degranulation responses similar to adults. However, neutrophils from preterm infants have a lower capacity to release BPI, elastase, and lactoferrin than in adults and term infants. G-CSF activates mature neutrophils without degranulation of primary granules, whereas GM-CSF induces degranulation and exocytosis of granule contents. However, anti-inflammatory agents such as corticosteroids and indomethacin inhibit the degranulation of secondary granules.
PMNs of term and preterm infants are limited in chemotactic, phagocytic, and microbicidal activities. The physiologic rationale for the use of hematopoietic growth factors to improve neutrophil function qualitatively and quantitatively has been well established. The use of G-CSF and GM-CSF has been shown to increase the neutrophil storage pool, induce neutrophilia, and improve many neutrophil functions. In meta-analysis, G-CSF administration was shown to reduce mortality in neonates with sepsis. However, when the nonrandomized studies were excluded, the analysis did not remain statistically adequate. G-CSF therapy is generally well tolerated in neonates, and many centers now use recombinant G-CSF in infants with severe neutropenia (absolute neutrophil counts <500 for 48 hours or between 500-1000 for more than 5-7 days). However, based on current literature, a clear recommendation for the use of these growth factors to decrease the incidence of morbidity and mortality associated with sepsis in newborns cannot yet be made. Further studies are needed in high-risk neonatal subgroups with sepsis, as preliminary evidence suggests that such an approach may be more effective. The newer, longer-acting polyethylene glycol-conjugated or glycosylated forms of G-CSF also hold promise as viable therapeutic alternatives.
The mononuclear phagocyte system comprises bone marrow monocyte precursors, circulating monocytes, and mature macrophages. As with the granulocyte lineage, mononuclear phagocytes are derived from CFU-GM progenitor cells. Several hematopoietic growth factors influence mononuclear phagocyte production. CSF-1 or macrophage CSF is the major hematopoietic growth factor influencing maturation and production of mononuclear phagocytes. Cells of this lineage seem to be unique in expressing cell surface receptors for CSF-1. On leaving the bone marrow, monocytes circulate for nearly 72 hours and then migrate into tissues, where the local extracellular milieu strongly influences monocyte-to-macrophage differentiation. Although the ultimate fate of macrophages is unclear, these cells have been observed to live for several months in many human tissues.
Embryonic macrophages are first seen in the yolk sac at 3-4 weeks of gestation. Unlike macrophages in the fetus and the adult that are derived from circulating monocytes, these large-sized histiocytic cells develop in the early embryonic period from yolk sac progenitors prior to the first appearance of monocytes. At 5 weeks of gestation, two distinct cell lineages with a dendritic/macrophage structure can be identified in the yolk sac, mesenchyme, and the fetal liver. The larger subgroup is MHC II–negative, and there is only a minor population that expresses these antigens. MHC II–negative cells also appear in the thymic cortex, in the marginal zones of lymph nodes, in the splenic red pulp, and in the bone marrow. A few MHC II–positive cells are seen in the liver at 7-8 weeks of gestation, the lymph nodes at 11-13 weeks of gestation, and the T-cell areas of the developing thymic medulla by 16 weeks of gestation. Subsequently, the numbers increase gradually, and MHC class II–positive cells are also seen in the skin and gastrointestinal tract.
During the second month of gestation, as hematopoiesis becomes established in the fetal liver, monocytes are seen in high proportions and constitute nearly 70% of all hematopoietic cells. Over the next 6 weeks, as the erythroid cells predominate, this proportion falls to 1%-2%. The first monocytes in circulation are not seen until about the fifth month of gestation and remain uncommon until the bone marrow becomes the predominant site of hematopoiesis. At 30 weeks, monocytes comprise 3%-7% of hematopoietic cells. Term cord blood studies show a relative monocytosis, which persists during the neonatal period. Although there is some disagreement between various reports on normal blood monocyte counts in neonates, recently normal ranges of absolute monocyte counts using data from more than 62,000 blood counts have been described, where it was shown that blood monocyte concentrations increase almost linearly between 22-42 weeks’ gestation. Monocyte concentrations also increased during the first 2 postnatal weeks. These data are consistent with previous kinetic studies in human fetuses, which show a similar maturational increase in monocyte precursors. In neonates, monocytosis has been associated with lower birth weight and gestational age, multiple transfusions, albumin infusions, and theophylline therapy. Monocytosis has also been described in infants with congenital infections, such as candidiasis and syphilis, and immune-mediated neutropenia.
Monocyte-to-macrophage differentiation has been well characterized, but the control mechanisms involved remain elusive. As monocytes develop into macrophages, certain morphologic changes occur. The cells increase in diameter more than threefold and acquire more cytoplasmic granules and vacuoles. Differentiation is also associated with increased expression of cell surface receptors, biosynthesis of numerous biologically active molecules, and improved phagocytic activity. Similar to PMNs, all mononuclear phagocytes have a well-developed cytoskeletal apparatus that is important in determining cell mobility and participation in many adhesion-related functions.
Information on tissue macrophage kinetics in the neonatal period is mainly from autopsy studies. The size of the macrophage pool varies in different organ systems. In the gastrointestinal tract, macrophages appear in the lamina propria as early as 10 weeks of gestation, and a sizable macrophage population can be seen during midgestation. In contrast, the alveolar macrophage population remains small in the fetus and expands during the early neonatal period. This increase may result both from an influx of monocytes from the circulation as well as from clonal expansion in situ.
A lower proportion of cord blood macrophages stains for esterase, although there are no discernible differences in peroxidase activity. Neonatal monocytes have lower expression levels of the aforementioned surface markers, except for CD14. During infections, macrophages show an “activated” phenotype with enhanced phagocytic function, enhanced capacity to kill facultative intracellular micro-organisms. These cells can be identified by unique morphologic features like larger diameter and greater number of pseudopods and pinocytotic vesicles.
Unlike neutrophils, the major host defense functions of monocytes in cord blood of term infants are intact. Cord blood monocytes show adherence, random migration, bactericidal activity, phagocytosis-associated chemiluminescence, production of superoxide anion (O• 2 - ), and generation of hydrogen peroxide at levels comparable to those of cells from healthy adult volunteers. One exception may be in the ability of cord monocytes to ingest group B streptococci (GBS) . However, phagocytosis of GBS improved when neonatal monocytes were incubated with organisms preopsonized with fibronectin and IgG. The ability of fetal and neonatal monocytes to kill a variety of pathogens including S. aureus , S. epidermidis , E. coli , and C. albicans appears to be equivalent to that of adults.
Chemotaxis of cord blood monocytes is nearly normal, but monocytes isolated from the peripheral blood of newborns do not migrate normally. The chemotactic activity of these cells sequentially declines over the first week of life before slowly improving and achieving (by age 6 years) the chemotactic activity of monocytes isolated from the blood of adults. Impaired migration in response to chemoattractants may be a primary factor in the delayed influx of monocytes at inflammatory sites during the neonatal period.
Resident macrophages are often the first phagocytic cells of the innate immune system to encounter invading pathogens. These cells serve important host defense functions through phagocytosis and also as sentinel cells that regulate local inflammatory responses by producing various cytokines and chemokines. Most studies on monocyte/macrophage cell function have been done on cord blood, and fetal cells have not been studied to the same extent so far. Term cord-blood monocytes produce IL-1, IFN-α, and TNF in concentrations that are comparable to adults, but the levels of IFN-γ, IL-8, IL-10, and GM-CSF are lower. These cells also produce lower concentrations of extracellular proteins like fibronectin and bioreactive lipids like leukotriene B 4 . Impaired monocyte function in neonates may be partially responsible for poorer cytokine responses of neonatal T cells.
Generally, mononuclear phagocyte recruitment and accumulation lag behind the brisk PMN influx by 6-12 hours, but the former process persists for several days. In addition to the host defense functions, mononuclear phagocytes also help regulate the process of tissue debridement and initiation of wound repair. During resolution of inflammation, the macrophage populations switch from a pro-inflammatory to an anti-inflammatory phenotype. Emerging evidence indicates that macrophages are dynamic and heterogeneous cells, which are polarized into the classically activated M1 macrophages that express various inflammatory signals and the M2 macrophages that display an anti-inflammatory profile. The effect of development on macrophage polarization is unclear.
The influx of mononuclear phagocytes to sites of inflammation is delayed and attenuated in newborns. This defect is most likely related to the impaired chemotactic activity displayed by the peripheral blood monocytes of these infants. Phagocytosis and microbicidal activity seem equivalent to the level displayed by mononuclear phagocytes of adults. In vivo studies of macrophage function at birth and during the neonatal period are limited, but pulmonary alveolar macrophages seem to function normally in the infants examined to date.
The role of humoral factors in the enhancement of leukocyte phagocytosis of bacterial pathogens has been known since the turn of the 20th century. These heat-labile and heat-stable plasma proteins, called opsonins, consist mainly of serum antibodies and components of the complement system, although several other proteins seem to play important roles (see later). The opsonic activity of plasma or serum from newborn term infants is equivalent to activity measured in sera from adults until the test concentrations of plasma or serum are reduced to less than 10%. At low serum concentrations, opsonic activity against various bacteria and fungi is diminished during the neonatal period. Opsonic activity is reduced even more in premature infants and persists at test concentrations of plasma or serum greater than 10%. These deficiencies in opsonic activity may be related partly to lower complement and IgG and IgM concentrations in newborns. The complement system is described in the following section. The opsonic role and other functions of immunoglobulins are reviewed later, when antibodies are discussed as humoral components of specific immunity.
The complement system plays an important role as one of the principal humoral effector pathways of immunity. Its major function is to facilitate the neutralization of foreign substances either in the circulation or on mucous membranes. This function is accomplished by a series of plasma proteins that are involved in specific and nonspecific host defense mechanisms.
The classic pathway of complement activation requires the presence of specific antibodies against a particular antigen and the formation of immune complexes ( Fig. 47.4 ). Two antibody molecules of the immune complex are bridged by the first component of complement, C1, which initiates a chain reaction in which one activated component serves as the enzyme that cleaves the next component in line. The order of component activation in the classic pathway is C1, C4, C2, and C3. Peptides with different biologic activities are created and either remain attached to the site of activation or diffuse into the milieu. C1 is itself a multimeric complex consisting of C1q, C1r, and C1s. When C1q binds the Fc portion of IgG or IgM immune complexes, C1 is activated. This cleaves C4, generating the C4a and C4b fragments. C4b then cleaves C2 into C2a and C2b. The C4b2a complex binds to microbial surfaces and acts as the C3 convertase, a protease that cleaves the third component of complement, C3, into membrane-bound C3b and the fluid-phase C3a. With the generation of C3b, the classic pathway merges with the other mode of complement activation, the alternative pathway.
In contrast to the classic pathway, the alternative pathway may be activated by bacterial or mammalian cell surfaces in the absence of specific antibodies. This activation is possible because small amounts of C3 in the circulation are constantly being converted to C3b. This complement component can bind to cell surfaces, interact with the next alternative pathway components in sequence (factors B and D), and form a potent enzyme for further C3 activation (C3bBb). C3b originally generated by the classic pathway may involve this amplification loop of the alternative pathway and significantly enhance local C3 activation. The lectin pathway provides yet another mode of complement activation. This pathway is activated by binding of Mannose-binding lectins and ficolins with carbohydrate moieties on the surface of pathogens. These lectins are normally bound in complexes with MBL-associated serine proteases (MASP). Activation of MASP-2 results in cleavage of C4, forming C4a and C4b, which, as in the classical complement pathway, then cleaves C2 into C2a and C2b. The C4b2a complex that is then formed acts as the C3 convertase enzyme, resulting in C3 cleavage and activation.
The central location of C3 in the complement pathway is important not only because the classic and alternative pathways converge at this point, but also because many biologic effects are determined by the interaction of this important molecule with various regulatory systems. The direction in which the complement pathway proceeds depends on the surface to which the C3b molecule is bound. Certain bacteria and other membranes offer a “protective surface” that favors the binding of C3b to factors B and D and the assembly of the enzyme that converts the next component in line, C5, into two biologically active fragments. The smaller product, C5a, acts as an anaphylatoxin to promote many aspects of acute inflammation, including chemoattraction of leukocytes and increasing vascular permeability. The larger fragment, C5b, remains attached to the C5 convertase on the membrane and assembles the components of the membrane attack complex: C5b, C6, C7, C8, and C9. Insertion of this complex into the cell membrane results in loss of membrane functions and cellular integrity.
In the absence of a protected site, C3b is exposed to factors I and H, which facilitate cleavage of C3b into iC3b and C3d. All these fragments of C3 can function as ligands for cellular receptors, which are located on erythrocytes and almost all immunocompetent cells. The C3b receptor (CR1) is known to mediate adherence of complement-coated complexes to erythrocytes, neutrophils, and mononuclear phagocytes and plays an important role in the clearance of immune complexes, bacteria, and cellular debris from the circulation. Other receptors also have been identified, such as the C3b binding protein, CR2, which is found on B lymphocytes and eosinophils. Its function awaits clarification, but there is evidence that adherence of the Epstein-Barr virus is mediated by this receptor. Finally, the iC3b receptor (CR3, CD11b/CD18) seems to be important for the ability of the host to overcome bacterial invasion. As previously mentioned, patients with a genetic deficiency of leukocyte cell surface CR3 experience severe recurrent bacterial infections. In addition to their roles in innate immunity, complement receptors may play important roles in adaptive immunity. Both CR1 and CR2 receptors are present on B-lymphocytes and play roles in B-cell differentiation and responses when presented with antigens. Similarly, T cells express receptors for the anaphylotoxins C3a and C5a, which maintain T-cell proliferation, viability, and differentiation.
Complement proteins are synthesized early in gestation. Synthesis of C2, C3, C4, and C5 can be confirmed between 8 and 14 weeks of gestation. Most evidence, derived through several methods, confirms that there is no transplacental passage of complement components. The components of the classic and alternate complement system and their functional activity (measured by total hemolytic complement assay) in full-term neonates are generally lower than normal adults ( Table 47.1 ). Most serum alternative complement component values reach adult levels by 6-18 months of age. Proteins in the lectin pathway are also lower in neonates compared to adults and are decreased in preterm compared to term infants.
Complement Component | Mean Percentage of Adult Levels | |
---|---|---|
Term Neonate | Preterm Neonate | |
CH 50 | 52-81 | 32-78 |
AP 50 | 49-65 | 49-54 |
C1q | 53-73 | 27-37 |
C4 | 54-80 | 42-59 |
C2 | 62-77 | 69 |
C3 | 50-97 | 39-60 |
C5 | 67-79 | 60-71 |
C6 | 44-58 | 35-39 |
C7 | 67-120 | 73-75 |
C8 | 36-38 | 29 |
C9 | 14-55 | 33-56 |
B | 36-73 | 36-53 |
D | 120-129 | — |
P | 27-71 | 13-65 |
H | 56-73 | 60 |
I | 39-58 | 45 |
Whether deficiencies in the complement system predispose a neonate to infection has not as yet been established. Defects in the complement system and in the alternative pathway, in particular, are likely to play a role in susceptibility to infection, especially in preterm infants. Newborns have a limited spectrum of antibody transmitted across the placenta; they receive IgG, no IgM, and little antibody to the entire range of gram-negative bacteria. The classic pathway has relatively little value at and shortly after birth. It follows that, in the absence of specific antibody, activation of the biologically active fragments and complexes of the complement system through the alternative or lectin pathways becomes an extremely important defense mechanism for neonates during the first encounter with many bacteria. In most neonates, functional deficiencies in these pathways, in conjunction with impaired functioning of PMNs, is likely to be clinically relevant as suggested by lower levels of MBL and ficolin lectins in neonates with culture-proven sepsis.
Fibronectins are a class of multifunctional, high–molecular weight glycoproteins that serve to facilitate cell-to-cell and cell-to-substratum adhesion. Fibronectins play a key role in organogenesis and for hemostasis, hematopoiesis, inflammation, and wound healing. In many pathophysiologic conditions (e.g., sepsis, thrombosis, cancer, organ fibrosis), the normal structure, physiology, and function of fibronectins are altered in a way that contributes to the underlying tissue or organ dysfunction.
Fibronectins exist as soluble and insoluble dimeric molecules. Soluble fibronectins have been identified in nearly every body fluid tested (synovial, ocular, pleural, amniotic, cerebrospinal, and others). Insoluble fibronectins are present in many connective tissues and extracellular matrices throughout the body. It is apparent that structural variants (isoforms) of fibronectin exist and that expression of these isoforms is highly regulated in a cell-specific and tissue-specific fashion.
All fibronectins are capable of binding to multiple ligands simultaneously. The modular design of these glycoproteins translates into a linear array of active globular functional domains. Fibronectins display individual binding sites for some molecules and multiple sites for others. Fibronectins bind certain bacteria, heparin, fibrin, IgG, and DNA in several separate domains, but other bacteria, matrix molecules, actin, complement component C1q, and gangliosides are bound at unique sites in individual domains. In this way, fibronectin facilitates the interaction of cells with other cells, bacteria, tissues, particles, and soluble proteins.
Circulating plasma fibronectin concentrations are reduced in fetal cord blood (120 fg/mL) and in term infants (220 fg/mL). Premature infants of 30-31 weeks’ gestation have significantly lower plasma concentrations (152 fg/mL) than term infants. Lower plasma concentrations in neonates are correlated with decreased synthetic rates, but plasma clearance of fibronectin also is measurably slower. Plasma fibronectin concentrations are reduced further in infants with respiratory distress syndrome, birth depression, sepsis, and intrauterine growth restriction.
Fibronectin improves leukocyte function in vitro. Plasma fibronectin and proteolytic fragments of fibronectins promote human adult peripheral blood neutrophil and monocyte chemotaxis, adhesion, and random migration. In addition, fibronectin enhances phagocyte ingestion, reactive oxygen intermediate production, and killing of opsonized (complement or IgG) yeast and bacterial organisms. Fibronectin seems to play an important role as an enhancer of phagocyte function.
Circulating concentrations of fibronectin are decreased in the neonatal period and are correlated with gestational age. Even lower plasma concentrations are measured in infants who are ill. Plasma fibronectin increases phagocyte function in vitro. The role of fibronectin in host immune defense in neonates remains uncertain, but in vitro data suggest a potential role as an enhancer of phagocyte function.
Become a Clinical Tree membership for Full access and enjoy Unlimited articles
If you are a member. Log in here